Randomized trial on chest irradiation in extensive disease small cell lung cancer.

Completed

• Conditions: PCI; SCLC; ED-SCLC; thoracic radiotherapy; brain metastasis; prophylactic cranical irradiation; extensive disease small cell lung cancer; klein-cellig longkanker; radiotherapie

• Registration Number: NL-OMON21608
• Lead Sponsor: VU University medical centerDept. of Radiation Oncology

Brief Summary

se of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial , Slotman et al. The Lancet September 14, 2014 <br> http://dx.doi.org/10.1016/ S0140-6736(14)61085-0 <br> Comments in http://dx.doi.org/10.1016/ S0140-6736(14)61252-6

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 483

Inclusion Criteria

Cytologically or histologically proven small cell lung cancer
-Documented extensive disease (see appendix D) before the start of chemotherapy

Exclusion Criteria

None

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint of this trial is to achieve an increase in 1 year survival of 10% (from 27% to 37%; HR=0.76). <br /><br>The Kaplan-Meier method will be used to estimate survival at different time points, and the logrank two sided test will be used to compare therapeutic arms according to the intent to treat policy.<br>

Secondary Outcome Measures

Name	Time	Method
The secondary endpoints are local control, pattern of failure and toxicity. Local control is defined as the absence of disease progression in the treated lobe/lung.